Kazia Therapeutics Aktien im Umlauf
Was ist das Aktien im Umlauf von Kazia Therapeutics?
Aktien im Umlauf von Kazia Therapeutics Limited ist 132.037M
Was ist die Definition von Aktien im Umlauf?
Im Umlauf befindliche Aktien sind alle Aktien einer Gesellschaft oder eines finanziellen Vermögenswertes, die von Anlegern genehmigt, ausgegeben und gekauft wurden und von diesen gehalten werden.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Aktien im Umlauf von Unternehmen in Health Care Sektor auf ASX im Vergleich zu Kazia Therapeutics
Was macht Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Unternehmen mit aktien im umlauf ähnlich Kazia Therapeutics
- Flir Systems hat Aktien im Umlauf von 131.932M
- Skyharbour Resources hat Aktien im Umlauf von 131.954M
- Jubilant FoodWorks hat Aktien im Umlauf von 131.969M
- Jubilant FoodWorks hat Aktien im Umlauf von 131.969M
- Shanghai Jiaoda Withub Information Industrial hat Aktien im Umlauf von 132.000M
- Upwork Inc hat Aktien im Umlauf von 132.007M
- Kazia Therapeutics hat Aktien im Umlauf von 132.037M
- Vulcan Materials hat Aktien im Umlauf von 132.048M
- Vulcan Materials Co hat Aktien im Umlauf von 132.060M
- Covia hat Aktien im Umlauf von 132.098M
- REA hat Aktien im Umlauf von 132.117M
- Albion Technology & General VCT Plc hat Aktien im Umlauf von 132.131M
- Outcrop Gold hat Aktien im Umlauf von 132.149M